{"id":62781,"date":"2026-04-10T13:09:18","date_gmt":"2026-04-10T05:09:18","guid":{"rendered":"https:\/\/flcube.com\/?p=62781"},"modified":"2026-04-10T13:09:21","modified_gmt":"2026-04-10T05:09:21","slug":"duality-biologics-her2-targeted-adc-db-1303-bnt323-enters-nmpa-review-for-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62781","title":{"rendered":"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer"},"content":{"rendered":"\n<p><strong>Duality Biologics Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9606:HKG\">HKG: 9606<\/a>), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its <strong>New Drug Application (NDA)<\/strong> for <strong>DB-1303<\/strong> (development code <strong>BNT323<\/strong>, in partnership with <strong>BioNTech SE<\/strong>) for formal review. The filing seeks approval for the treatment of <strong>HER2-positive unresectable or metastatic breast cancer<\/strong> in patients previously treated with <strong>trastuzumab and taxanes<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-development-snapshot\">Regulatory &amp; Development Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Candidate<\/strong><\/td><td>DB-1303 \/ BNT323<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>HER2-targeted Antibody-Drug Conjugate (ADC)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Proprietary <strong>DITAC<\/strong> (Duality Immune Toxin Antibody Conjugate)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>BioNTech SE (NASDAQ: BNTX)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NDA accepted by NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>2L+ HER2+ metastatic\/unresectable breast cancer<\/td><\/tr><tr><td><strong>Basis for Filing<\/strong><\/td><td>Positive Phase III DB-1303-O-3001 trial vs. T-DM1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-iii-trial-highlights-db-1303-o-3001\">Phase III Trial Highlights (DB-1303-O-3001)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint:<\/strong> <strong>Progression-Free Survival (PFS)<\/strong> \u2014 met with <strong>statistical significance and clinical meaningfulness<\/strong> per independent Data Monitoring Committee (IDMC)<\/li>\n\n\n\n<li><strong>Comparator:<\/strong> Standard-of-care <strong>T-DM1<\/strong> (ado-trastuzumab emtansine)<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> HER2+ metastatic breast cancer patients post trastuzumab + taxane<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Favorable tolerability with no unexpected adverse events; consistent with prior studies<\/li>\n<\/ul>\n\n\n\n<p>The DITAC platform enables enhanced tumor-selective delivery of cytotoxic payloads, potentially improving therapeutic index over conventional ADC architectures.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-amp-commercial-outlook\">Strategic &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity:<\/strong> China accounts for ~20% of global HER2+ breast cancer cases, with growing demand for next-generation ADCs beyond T-DM1<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> DB-1303\u2019s novel linker-payload design may offer improved efficacy and reduced toxicity versus existing HER2 ADCs<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Concurrent regulatory pathways under evaluation with international partners; China filing represents first major market submission<\/li>\n\n\n\n<li><strong>Pipeline Context:<\/strong> DB-1303 is Duality\u2019s most advanced asset, with potential to become the company\u2019s first commercial product<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory review timelines, clinical data interpretation, and commercial potential. Actual outcomes are subject to NMPA decisions, competitive dynamics, and further clinical validation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901795_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040901795_c.\"><\/object><a id=\"wp-block-file--media-c35c56b5-f43e-4998-885a-a96b9ce81f2a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901795_c.pdf\">2026040901795_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901795_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c35c56b5-f43e-4998-885a-a96b9ce81f2a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,232,3974,38],"class_list":["post-62781","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-duality-biologics","tag-hkg-9606","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for DB-1303 (development code BNT323, in partnership with BioNTech SE) for formal review. The filing seeks approval for the treatment of HER2-positive unresectable or metastatic breast cancer in patients previously treated with trastuzumab and taxanes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62781\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for DB-1303 (development code BNT323, in partnership with BioNTech SE) for formal review. The filing seeks approval for the treatment of HER2-positive unresectable or metastatic breast cancer in patients previously treated with trastuzumab and taxanes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62781\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-10T05:09:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T05:09:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62781#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62781\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer\",\"datePublished\":\"2026-04-10T05:09:18+00:00\",\"dateModified\":\"2026-04-10T05:09:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62781\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Duality Biologics\",\"HKG: 9606\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62781#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62781\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62781\",\"name\":\"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-10T05:09:18+00:00\",\"dateModified\":\"2026-04-10T05:09:21+00:00\",\"description\":\"Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for DB-1303 (development code BNT323, in partnership with BioNTech SE) for formal review. The filing seeks approval for the treatment of HER2-positive unresectable or metastatic breast cancer in patients previously treated with trastuzumab and taxanes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62781#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62781\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62781#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for DB-1303 (development code BNT323, in partnership with BioNTech SE) for formal review. The filing seeks approval for the treatment of HER2-positive unresectable or metastatic breast cancer in patients previously treated with trastuzumab and taxanes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62781","og_locale":"en_US","og_type":"article","og_title":"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer","og_description":"Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for DB-1303 (development code BNT323, in partnership with BioNTech SE) for formal review. The filing seeks approval for the treatment of HER2-positive unresectable or metastatic breast cancer in patients previously treated with trastuzumab and taxanes.","og_url":"https:\/\/flcube.com\/?p=62781","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-10T05:09:18+00:00","article_modified_time":"2026-04-10T05:09:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62781#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62781"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer","datePublished":"2026-04-10T05:09:18+00:00","dateModified":"2026-04-10T05:09:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62781"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Duality Biologics","HKG: 9606","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62781#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62781","url":"https:\/\/flcube.com\/?p=62781","name":"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-10T05:09:18+00:00","dateModified":"2026-04-10T05:09:21+00:00","description":"Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for DB-1303 (development code BNT323, in partnership with BioNTech SE) for formal review. The filing seeks approval for the treatment of HER2-positive unresectable or metastatic breast cancer in patients previously treated with trastuzumab and taxanes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62781#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62781"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62781#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality Biologics\u2019 HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62781"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62781\/revisions"}],"predecessor-version":[{"id":62783,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62781\/revisions\/62783"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}